This article is more than 5 years old. Information may no longer be current.
C.R. Bard Acquires PTA Balloon Manufacturer
Click Here to Manage Email Alerts
C.R. Bard has purchased Lutonix, manufacturer of a drug-coated percutaneous transluminal angioplasty balloon, for approximately $225 million, with an additional $100 million to be paid to Lutonix with the pre-market approval of the percutaneous balloon.
According to a press release, the acquisition is structured as a merger, which C.R. Bard expects will reduce 2012 earnings per share by approximately 25 cents, excluding items that affect comparability.
Currently, Lutonix is conducting an investigational device exemption trial testing drug-coated balloons for the treatment of peripheral arterial disease, an indication currently untreated by any such device in the United States. The randomized, prospective, single blind, multicenter LEVANT 2 trial will compare the drug-coated balloon to standard balloon angioplasty in 476 patients with significant stenosis of the superficial femoral artery or popliteal artery with lesions up to 150 mm in length. The trial will be conducted in 55 sites in the United States and Europe.
In 2011, Lutonix received CE mark approval for its drug-coated balloon, and C.R. Bard expects to begin selling the device in Europe in the second half of 2012. C.R. Bard has also begun planning a larger registry study concurrent with the launch in Europe to gather additional clinical data and support broader marketing claims.